Analysen von Michael J. Yee
| 19.01.12 | Amgen outperform | RBC Capital Markets | |
| 19.01.12 | Auxilium Pharmaceuticals outperform | RBC Capital Markets | |
| 18.01.12 | Celgene outperform | RBC Capital Markets | |
| 18.01.12 | Regeneron Pharmaceuticals outperform | RBC Capital Markets | |
| 13.01.12 | Human Genome Sciences outperform | RBC Capital Markets | |
| 11.01.12 | Regeneron Pharmaceuticals outperform | RBC Capital Markets | |
| 12.12.11 | Celgene outperform | RBC Capital Markets | |
| 08.12.11 | ImmunoGen outperform | RBC Capital Markets | |
|
Werbung
|
|||
| 08.12.11 | Amgen outperform | RBC Capital Markets | |
| 06.12.11 | Elan outperform | RBC Capital Markets | |
| 06.12.11 | Cubist Pharmaceuticals outperform | RBC Capital Markets | |
| 01.12.11 | Celgene outperform | RBC Capital Markets | |
| 28.11.11 | Gilead Sciences outperform | RBC Capital Markets | |
| 21.11.11 | Regeneron Pharmaceuticals outperform | RBC Capital Markets | |
| 16.11.11 | Gilead Sciences outperform | RBC Capital Markets | |
| 15.11.11 | Regeneron Pharmaceuticals outperform | RBC Capital Markets | |
| 15.11.11 | Elan outperform | RBC Capital Markets | |
| 14.11.11 | Biogen outperform | RBC Capital Markets | |
| 03.11.11 | Celgene outperform | RBC Capital Markets | |
| 03.11.11 | Vertex Pharmaceuticals outperform | RBC Capital Markets | |
| 28.10.11 | Human Genome Sciences outperform | RBC Capital Markets | |
| 26.10.11 | Cubist Pharmaceuticals outperform | RBC Capital Markets | |
| 26.10.11 | Amgen outperform | RBC Capital Markets | |
| 21.10.11 | Biogen outperform | RBC Capital Markets | |
| 20.10.11 | Cubist Pharmaceuticals outperform | RBC Capital Markets | |
| 18.10.11 | Acorda Therapeutics, outperform | RBC Capital Markets | |
| 14.10.11 | Human Genome Sciences outperform | RBC Capital Markets | |
| 14.10.11 | Biogen outperform | RBC Capital Markets | |
| 13.10.11 | Elan outperform | RBC Capital Markets | |
| 13.10.11 | Vertex Pharmaceuticals outperform | RBC Capital Markets | |
| 06.10.11 | Regeneron Pharmaceuticals outperform | RBC Capital Markets | |
| 06.10.11 | Amgen outperform | RBC Capital Markets | |
| 06.10.11 | Biogen outperform | RBC Capital Markets | |
| 06.10.11 | Gilead Sciences outperform | RBC Capital Markets | |
| 04.10.11 | Vertex Pharmaceuticals outperform | RBC Capital Markets | |
| 29.09.11 | Biogen outperform | RBC Capital Markets | |
| 27.09.11 | ImmunoGen outperform | RBC Capital Markets | |
| 23.09.11 | SIGA Technologies outperform | RBC Capital Markets | |
| 22.09.11 | Regeneron Pharmaceuticals outperform | RBC Capital Markets | |
| 21.09.11 | Gilead Sciences outperform | RBC Capital Markets | |
| 14.09.11 | Amgen outperform | RBC Capital Markets | |
| 09.09.11 | Human Genome Sciences outperform | RBC Capital Markets | |
| 07.09.11 | Gilead Sciences outperform | RBC Capital Markets | |
| 29.08.11 | Biogen outperform | RBC Capital Markets | |
| 23.08.11 | Gilead Sciences outperform | RBC Capital Markets | |
| 18.08.11 | Regeneron Pharmaceuticals outperform | RBC Capital Markets | |
| 11.08.11 | Gilead Sciences outperform | RBC Capital Markets | |
| 11.08.11 | XenoPort outperform | RBC Capital Markets | |
| 11.08.11 | Xoma outperform | RBC Capital Markets | |
| 04.08.11 | Biogen outperform | RBC Capital Markets | |